Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.45 |
| ▸ | PRKDC | P78527 | 13/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.43 |
| ▸ | MTOR | P42345 | 6/20 | 0.40 |
| ▸ | HPD | P32754 | 2/20 | 0.40 |
| ▸ | USP14 | P54578 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838061 | 0.83 | DRD2 (0.49) | DRD2SLC6A4DDB1CRBNPRKDC | |
| SCHEMBL5838051 | 0.83 | DRD2 (0.52) | DRD2SLC6A4DDB1CRBNPRKDC | |
| SCHEMBL22862859 | 0.80 | POLB (0.49) | — | |
| SCHEMBL5836683 | 0.80 | KDM4E (0.50) | DRD2SLC6A4DDB1CRBNPRKDC | |
| SCHEMBL6208794 | 0.72 | HPD (0.56) | DRD2SLC6A4PRKDCPIK3CAMTOR | |
| SCHEMBL5836181 | 0.69 | HPD (0.53) | DRD2SLC6A4PRKDCPIK3CAMTOR | |
| SCHEMBL25406066 | 0.69 | DRD2 (0.51) | DRD2SLC6A4DDB1CRBNPRKDC | |
| SCHEMBL5838497 | 0.69 | HPD (0.44) | DDB1CRBNPRKDCPIK3CAMTOR | |
| SCHEMBL30733897 | 0.69 | DDB1 (0.40) | DRD2SLC6A4DDB1CRBNPRKDC | |
| SCHEMBL20861040 | 0.68 | PIK3CA (0.53) | DDB1CRBNPRKDCPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056918-B2 | Benzimidazole anti-inflammatory compounds | PFIZER, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1370557-B1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1370557-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002072576-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | MAPK1, JAK1, CNKSR1 | DRD2 4329/4885SLC6A4 4649/4885DDB1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.